ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i5.1166ppharm-53Research ArticleВАКЦИНАЦИЯ В СОВРЕМЕННОМ МИРЕVACCINATIONОПЫТ ПРИМЕНЕНИЯ И ОЦЕНКА БЕЗОПАСНОСТИ 13-ВАЛЕНТНОЙ ПНЕВМОКОККОВОЙ КОНЪЮГИРОВАННОЙ ВАКЦИНЫ У ДЕТЕЙ МЛАДШЕ 5 ЛЕТEXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDRENФедосеенкоМ. В.FedoseenkoM. V.

кандидат медицинских наук, старший научный сотрудник отделения вакцинопрофилактики детей с отклонениями в состоянии здоровья НИИ профилактической педиатрии и восстановительного лечения ФГБНУ Научного центра здоровья детей Адрес: 119991, Москва, Ломоносовский проспект, д. 2/62, тел.: +7 (499) 134-20-92;

titovamarina@mail.ruНовиковаД. А.NovikovaD. A.titovamarina@mail.ruТкаченкоН. Е.TkachenkoN. E.titovamarina@mail.ruБроеваМ. И.BroevaM. I.titovamarina@mail.ruГречухаТ. А.GrechukhaT. A.titovamarina@mail.ruГайворонскаяА. Г.GaivoronskayaA. G.titovamarina@mail.ruЧерниковВ. В.ChernikovV. V.titovamarina@mail.ruНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Moscow, Russian FederationRussian FederationНаучный центр здоровья детей, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian Federation201401102014115Педиатрическая фармакология5964Copyright © Федосеенко М.В., Новикова Д.А., Ткаченко Н.Е., Броева М.И., Гречуха Т.А., Гайворонская А.Г., Черников В.В., 20142014Федосеенко М.В., Новикова Д.А., Ткаченко Н.Е., Броева М.И., Гречуха Т.А., Гайворонская А.Г., Черников В.В.Fedoseenko M.V., Novikova D.A., Tkachenko N.E., Broeva M.I., Grechukha T.A., Gaivoronskaya A.G., Chernikov V.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/53

Обязательное использование 7-валентной пневмококковой конъюгированной вакцины в национальных схемах педиатрической иммунизации на территориях развитых стран мира привело к значительному снижению количества случаев пневмококковых инфекций, вызванных серотипами, входящими в состав вакцины. Однако, наряду с этим был отмечен рост заболеваемости пневмонией, острым средним отитом, ответственными за которые выступают невакцинные штаммы. Это потребовало внедрения новой 13-валентной пневмококковой конъюгированной вакцины с более широким спектром покрытия пневмококковой популяции. Накопленный опыт применения (с 2010 г.) в разных странах мира, а также результаты собственных наблюдений свидетельствуют о высоком уровне безопасности 13-валентной пневмококковой конъюгированной вакцины как у здоровых детей до 5-летнего возраста, так и у пациентов с различными отклонениями в состоянии здоровья. В статье приведены результаты оценки переносимости вакцинации 13-валентной пневмококковой конъюгированной вакциной. В исследовании участвовали 110 детей в возрасте от 2 мес до 5 лет. В большинстве случаев иммунизация была совмещена с другими педиатрическими вакцинами. Частота местных реакций у привитых детей не превышала 33%, общих реакций ― 11%. Установлено сопоставимое число побочных реакций как у практически здоровых, так и детей с различными отклонениями в состоянии здоровья.

 

Compulsory use of the 7-valent pneumococcal conjugate vaccine in the framework of national pediatric immunization schedules of the developed countries resulted in significant decrease in the prevalence of the pneumococcal infections induced by the vaccinal serotypes. However, a growth in prevalence of the pneumonia and acute otitis media caused by non-vaccinal strains has also been observed. This required introduction of a new 13-valent pneumococcal conjugate vaccine with a wider range of pneumococcal population coverage. The experience of application accumulated in various countries (2010 onwards) and results of the authors’ observations indicate high safety of the 13-valent pneumococcal conjugate vaccine for both healthy under-5 children and patients with various medical issues. The article presents results of the 13-valent pneumococcal conjugate vaccination tolerance assessment. The study involved 110 children from 2 months to 5 years of age. In most cases immunization concurred with other pediatric vaccines. The incidence of local reactions in vaccinated children did not exceed 33%, of generalized reactions – 11%. The authors observed a comparable incidence of side reactions in both virtually healthy children and children with various medical issues.

пневмококковая инфекциявакцинация13-валентная пневмококковая конъюгированная вакцина (ПКВ13)безопасность вакцинациидетиpneumococcal infectionvaccination13-valent pneumococcal conjugate vaccine (PCV13)vaccination safetychildrenReferencesEstimated Hib and pneumococcal deaths for children under 5 years of age, 2008. World Health Organization. 2012; March. URL: http://apps.who.int/immunization_monitoring/burden/Pneumo_ hib_estimates/en/index.htmlEstimated Hib and pneumococcal deaths for children under 5 years of age, 2008. World Health Organization. 2012; March. Available at: http://apps.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/index.htmlWHO Global Immunization Vision and Strategy, April 2005. URL: www.who.int/vaccines/GIVS/english/Global_imm._data_EN.pdfWHO Global Immunization Vision and Strategy, April 2005. Available at: www.who.int/vaccines/GIVS/english/Global_imm._data_EN.pdfBocchini J. A. Jr., Bradley J. S., Brady M. T., Bernstein H. H., Byington C. L., Fisher M. C., Glode M. P., Jackson M. A., Key se r ling H. L., Kimberlin D. W., Orenstein W. A., Schutze G. E., Willo ugh by R. E. Jr. Recommendations for the Prevention of Streptococcus pneumonia Infections in Infants and Children: Use of 13-valent Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccaride Vaccine. Pediatrics. 2010 Jul; 126 (1): 186–90.Bocchini J.A. Jr., Bradley J.S., Brady M.T., Bernstein H.H., Byington C.L., Fisher M.C., Glode M.P., Jackson M.A., Keyserling H.L., Kimberlin D.W., Orenstein W.A., Schutze G.E., Willoughby R.E. Jr. Recommendations for the Prevention of Streptococcus pneumonia Infections in Infants and Children: Use of 13-valent Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccaride Vaccine. Pediatrics. 2010 Jul; 126 (1): 186−90.Paradiso P. R. Advances in pneumococcal disease prevention: 13-valent Pneumococcal Conjugate Vaccine for Infants and Children. Clin Infect Dis. 2011; 52 (10): 1241–1247.Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent Pneumococcal Conjugate Vaccine for Infants and Children. Clin Infect Dis. 2011; 52 (10): 1241−1247.Bettinger J. A., Scheifele D. W., Kellner J. D., Halperin S. A., Vaudry W., Law B., Tyrrell G., Morris R., Halperin S., Dеry P., Moore D., Lebel M., Le Saux N., Tran D., Embree J., Tan B., Jadavji T., Vaudry W., Sauvе L. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine. 2010; 28: 2130–6.Bettinger J.A., Scheifele D.W., Kellner J.D., Halperin S.A., Vaudry W., Law B., Tyrrell G., Morris R., Halperin S., Dеry P., Moore D., Lebel M., Le Saux N., Tran D., Embree J., Tan B., Jadavji T., Vaudry W., Sauvе L. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine. 2010; 28: 2130−6.Lehmann D., Willis J., Moore H. C., Moore H. C., Giele C., Murphy D., Keil A. D., Harrison C., Bayley K., Watson M., Richmond P. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis. 2010; 50: 1477–86.Lehmann D., Willis J., Moore H.C., Moore H.C., Giele C., Murphy D., Keil A.D., Harrison C., Bayley K., Watson M., Richmond P. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis. 2010; 50: 1477−86.Ruckinger S., van der Linden M., Reinert R. R., von Kries R., Burckhardt F., Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009; 27: 4136–41.Rückinger S., van der Linden M., Reinert R.R., von Kries R., Burckhardt F., Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009; 27: 4136−41.Vestrheim D. F., Lovoll O., Aaberge I. S., Caugant D. A., Hоiby E. A., Bakke H., Bergsaker M. R. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008; 26: 3277–81.Vestrheim D.F., Lovoll O., Aaberge I.S., Caugant D.A., Hоiby E.A., Bakke H., Bergsaker M.R. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008; 26: 3277−81.Food and Drug Administration. Vaccines: approved pro ducts. Prevenar 13 (pneumococcal 13-valent conjugate vaccine). URL: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Approved Products/ucm201667.htm. Accessed March 5, 2010.Food and Drug Administration. Vaccines: approved products. Prevenar 13 (pneumococcal 13-valent conjugate vaccine). Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm. Accessed March 5, 2010.Федосеенко М. В., Намазова-Баранова Л. С. Международный опыт применения пневмококковых конъюгированных вакцин: проблемы, достижения, перспективы. Вопросы современной педиатрии. 2009; 8 (1): 136–9.Fedoseenko M.V., Namazova-Baranova L.S. International experience of pneumococcal conjugate vaccines: challenges, achievements and prospects. Voprosy sovremennoi pediatrii = Current Pediatrics. 2009; 8 (1): 136−9.Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children — Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report (MMWR). Weekly. 2010 March 12; 59 (09): 258–61.Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children ― Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report (MMWR). Weekly. 2010 March 12; 59 (09): 258−61.Баранов А. А., Намазова-Баранова Л. С., Маянский Н. А. с соавт. Роль Streptococcus pneumoniae в структуре бактериальных инфекций у детей, госпитализированных в стационары г. Москвы в 2011–2012 гг. Педиатрическая фармакология. 2013; 10 (5): 6–13.Baranov A.A., Namazova-Baranova L.S., Mayanskii N.A. et al. The role of Streptococcus pneumoniae in the structure of bacterial infections in children admitted to hospitals in Moscow in 2011-2012. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (5): 6−13.Козлов Р. С. Пневмококковая инфекция: современные подходы к профилактике и терапии. Лекции для практикующих врачей. М.: Здоровье человека. 2005. С. 219–234.Kozlov R.S. Pnevmokokkovaya infektsiya: sovremennye podkhody k profilaktike i terapii. Lektsii dlya praktikuyushchikh vrachei [Pneumococcal Disease: Current Approaches to Prevention and Therapy. Lectures for Practitioners]. Moscow, Zdorov'e cheloveka, 2005. P. 219−234.Thompson A., Gurtman A., Patterson S. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013 Oct 25; 31 (45): 5289–95.Thompson A., Gurtman A., Patterson S. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013 Oct 25; 31 (45): 5289−95.Ruiz-Aragon J. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis. Vaccine. 2013; 31: 5349–58.Ruiz-Aragón J. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis. Vaccine. 2013; 31: 5349−58.Bryant K. A., Block S. L., Baker S. A. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010 May; 125 (5): 866–75.Bryant K.A., Block S.L., Baker S.A. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010 May; 125 (5): 866−75.Esposito S., Tansey S., Thompson A. Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers. Clin Vaccine Immunol. 2010 Jun; 17 (6): 1017–26.Esposito S., Tansey S., Thompson A. Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers. Clin Vaccine Immunol. 2010 Jun; 17 (6): 1017–26.Vanderkoii O. G., Scheifele D. W., Girgenti D., Halperin S. A., Patterson S. D., Gruber W. C., Emini E. A., Scott D. A., Kellner J. D. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccination in Canada. Pediatr Infect Dis J. 2012 Jan; 31 (1): 72–7.Vanderkoii O.G., Scheifele D.W., Girgenti D., Halperin S.A., Patterson S.D., Gruber W.C., Emini E.A., Scott D.A., Kellner J.D. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccination in Canada. Pediatr Infect Dis J. 2012 Jan; 31 (1): 72−7.Kieninger D. M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., Jansen K. U., Devlin C., Gruber W. C., Emini E. A., Scott D. A. Safety, tolerability and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccination in Germany. Vaccine. 2010 Jun; 7 (28): 25.Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., Jansen K.U., Devlin C., Gruber W.C., Emini E.A., Scott D.A. Safety, tolerability and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccination in Germany. Vaccine. 2010 Jun; 7 (28): 25.Togashi T., Yamaji M., Thompson A., Giardina P. C., Aizawa M., Patterson S., Gruber W. C., Scott D. A. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in health infants in Japan. Pediatr Infect Dis J. 2013 Sep; 32 (9): 984–9.Togashi T., Yamaji M., Thompson A., Giardina P.C., Aizawa M., Patterson S., Gruber W.C., Scott D.A. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in health infants in Japan. Pediatr Infect Dis J. 2013 Sep; 32 (9): 984−9.Gutierez Brito M., Thompson A., Girgenti D., Giardina P. C., Sarkozy D. A., Gruber W. C., Emini E. A., Scott D. A. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. Rev Panam Salud Publica. 2013 Jun; 33 (6): 414–21.Gutierez Brito M., Thompson A., Girgenti D., Giardina P.C., Sarkozy D.A., Gruber W.C., Emini E.A., Scott D.A. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. Rev Panam Salud Publica. 2013 Jun; 33 (6): 414−21.Weckx L. Y., Thompson A., Berezin E. N., de Faria S. M., da Cunha C. A., Pride M., Patterson S., Gruber W. C., Emini E. A., Scott D. A. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012 Dec 14; 30 (52): 7566–72.Weckx L.Y., Thompson A., Berezin E.N., de Faria S.M., da Cunha C.A., Pride M., Patterson S., Gruber W.C., Emini E.A., Scott D.A. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012 Dec 14; 30 (52): 7566−72.Tseng H. F., Sy L. S., Liu I. L., Qian L., Marcy S. M., Weintraub E., Yih K., Baxter R., Glanz J. M., Donahue J., Naleway A., Nordin J., Jacobsen S. J. Postlicenzure surveillance for pre-specified adverse events following the 13-vallent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31 (22): 2578–83.Tseng H.F., Sy L.S., Liu I.L., Qian L., Marcy S.M., Weintraub E., Yih K., Baxter R., Glanz J.M., Donahue J., Naleway A., Nordin J., Jacobsen S.J. Postlicenzure surveillance for pre-specified adverse events following the 13-vallent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31 (22): 2578−83.Ильина С. В., Белецкая О. А., Сабитов А. У., Черная Н. Л., Снегова Н. Ф., Салкина О. А., Джумагазиев А. А., Бахарева Н. В., Бров кина А. А., Саввина Н. В. Результаты оценки эффективности и безопасности применения конъюгированных пневмококковых вакцин в Российской Федерации. Эпидемиология и инфекционные болезни, актуальные вопросы. 2013; 6: 55–60.Il'ina S.V., Beletskaya O.A., Sabitov A.U., Chernaya N.L., Snegova N.F., Salkina O.A., Dzhumagaziev A.A., Bakhareva N.V., Brovkina A.A., Savvina N.V. The results of evaluation of the effectiveness and safety of conjugate pneumococcal vaccines in the Russian Federation. Epidemiologiya i infektsionnye bolezni, aktual'nye voprosy = Epidemiology and infectious diseases, topical issues. 2013; 6: 55−60.Ильина С. В., Лысанов Ю. И. Вакцинация конъюгированной пневмококковой вакциной недоношенных детей и детей с врожденными пороками сердца в Иркутске. Педиатрическая фармакология. 2013; 10 (3): 12–16.Il'ina S.V., Lysanov Yu.I. Vaccination Pneumococcal conjugate vaccine in preterm infants and children with congenital heart disease in Irkutsk. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (3): 12−16.Гайворонская А. Г., Намазова-Баранова Л. С., Галицкая М. Г., Гречуха Т. А., Ткаченко Н. Е., Ивардава М. И. Анализ эффективности и безопасности вакцинации против пневмококковой инфекции детей с различными отклонениями в состоянии здоровья. Педиатрическая фармакология. 2012; 9 (2): 10–14.Gaivoronskaya A.G., Namazova-Baranova L.S., Galitskaya M.G., Grechukha T.A., Tkachenko N.E., Ivardava M.I. Analysis of the efficacy and safety of vaccination against pneumococcal disease for children with various disabilities in health. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (2): 10−14.

The authors declare that there are no conflicts of interest present.